🔗 Share this article

Given that America undertakes historic revisions to its vaccination recommendations, an unexpected name has emerged somewhat surprisingly: Høeg, a US-based sports medicine doctor and epidemiologist who initially gained attention by casting doubt on coronavirus shots in the global health crisis and has zeroed in on possible fatalities after Covid vaccination in her brief tenure at the FDA.

Planned Changes to Childhood Vaccine Schedule

Health officials had intended to unveil radical changes to the childhood vaccine schedule earlier this month, bringing the US with Denmark’s national calendar, sources say – a substantial departure that would put the US at odds with a large portion of the world with no evidence for improved outcomes. The announcement has been delayed until the coming year.

Instead of the director of the vaccine center, Dr. Høeg is scheduled to address the audience at the gathering. She was just designated temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to run the center this year.

A New Direction at the FDA

The acting appointment might represent a tighter collaboration between the pharmaceutical and biologics centers as Dr. Høeg and Dr. Prasad solidify control at the agency – and it suggests a increased emphasis upon reevaluating long-standing immunizations at the FDA.

The new acting director has repeatedly called for halting certain pediatric immunization guidelines in the US in order to be more in line with the Danish model, a society with universal health coverage and a population about the size of Wisconsin’s.

So far public appearances, she has continued to focus on immunizations – typically the responsibility of Dr. Prasad, chief of the FDA’s CBER – instead of pharmaceutical oversight.

Doubts Over Background

Dr. Høeg has no apparent experience in pharmaceutical research, oversight or leadership, which has been typical for previous directors of the biologics center. She has been employed at the FDA as a senior adviser to the FDA chief and the vaccine center since spring.

“She appears not to have any of the qualifications” for leading the drug-regulation department, stated Dr. Jonathan Howard. “She has not conducted a scientific study. She is not versed in running a large organization. She lacks background in pharmaceutical oversight.”

Former directors of the center would “be deeply familiar with legal statutes and the underlying principles of pharmaceutical innovation”, commented Janet Woodcock. “Frankly, she has not acquired the sort of resume that prior appointees who led CBER have had.”

This division has an immense portfolio at the agency, she emphasized.

“Many people just zeroes in on the new drug program, but the generic program approves a multitude of generic medications. There’s a biosimilars division, OTC medication office and so forth, and each of these must be looked after,” she explained. “The area you neglect, that’s the thing that I always told people is going to come back to haunt you.”

Additionally, a major leadership element to the role, which manages in excess of 5,000 staff members. “It is a huge management job, if you do it right,” she added.

Agency Reaction and Contentious Initiatives

Regarding questions about Høeg’s qualifications and whether this assignment signifies increased cooperation among FDA leaders on immunizations, a spokesperson said that the “questions are based on incorrect assumptions”.

“Her resume matches the duties of her position,” the spokesperson explained, pointing to the period Høeg spent counseling the FDA commissioner on “medication safety and approval science, including computerized risk analysis and vaccine surveillance”.

As acting director, Høeg takes over the commissioner’s controversial priority voucher program, a controversial rapid medication authorization process that reportedly worried her former heads. “By what process are these drugs being selected for this expedited pathway? Who takes the decisions?” Dr. Howard said. “There is a lot of confidentiality happening at the FDA right now.”

Broadly speaking, he stated, “the Food and Drug Administration looks to be trending towards less stringent regulations of most medications, except for shots.”

Documented Track Record on Immunizations

Concerning immunizations, Høeg has a clearer, if troubling, track record, critics said. She published a study using unverified public submissions to estimate the incidence of heart inflammation after COVID-19 immunization. She counseled the Florida chief medical officer Dr. Joseph Ladapo, who was said to have altered data to suggest Covid vaccines are pose a greater threat than they are.

Part of her “desired changes” for the incoming federal leadership featured changing regulations for new vaccines and discontinuing “optional” immunizations, she remarked after the election on a podcast. At the FDA, Høeg has reportedly proposed excluding young men from obtaining COVID-19 vaccinations.

“She is an thorough dogmatist who commences with her beliefs and works backwards to fit the data in a extremely disingenuous, untruthful way,” Dr. Howard stated.

Gaining Influence and a “Revenge Tour”

Dr. Høeg joined other skeptics, {like|